Headlines about NovaBay Pharmaceuticals (NYSE:NBY) have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. NovaBay Pharmaceuticals earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.3711016536613 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of NovaBay Pharmaceuticals (NBY) traded up 1.62% on Friday, hitting $4.70. 29,698 shares of the stock traded hands. NovaBay Pharmaceuticals has a one year low of $2.25 and a one year high of $5.09. The stock has a 50 day moving average of $4.17 and a 200 day moving average of $3.66. The company’s market cap is $71.95 million.

NovaBay Pharmaceuticals (NYSE:NBY) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.01. NovaBay Pharmaceuticals had a negative net margin of 108.38% and a negative return on equity of 280.84%. The business had revenue of $4.12 million for the quarter, compared to analyst estimates of $4.57 million. Equities analysts anticipate that NovaBay Pharmaceuticals will post ($0.46) earnings per share for the current year.

Several equities research analysts recently issued reports on NBY shares. HC Wainwright set a $6.00 target price on shares of NovaBay Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 11th. Roth Capital set a $6.00 target price on shares of NovaBay Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, June 20th. Zacks Investment Research upgraded shares of NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 17th. Finally, Maxim Group restated a “hold” rating on shares of NovaBay Pharmaceuticals in a report on Saturday, May 13th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. NovaBay Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $7.00.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact NovaBay Pharmaceuticals (NBY) Share Price” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/20/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-novabay-pharmaceuticals-nby-share-price.html.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Insider Buying and Selling by Quarter for NovaBay Pharmaceuticals (NYSE:NBY)

Receive News & Stock Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.